Cargando…

Resveratrol as a Pan-HDAC Inhibitor Alters the Acetylation Status of Jistone Proteins in Human-Derived Hepatoblastoma Cells

The polyphenolic alcohol resveratrol has demonstrated promising activities for the prevention and treatment of cancer. Different modes of action have been described for resveratrol including the activation of sirtuins, which represent the class III histone deacetylases (HDACs). However, little is kn...

Descripción completa

Detalles Bibliográficos
Autores principales: Venturelli, Sascha, Berger, Alexander, Böcker, Alexander, Busch, Christian, Weiland, Timo, Noor, Seema, Leischner, Christian, Schleicher, Sabine, Mayer, Mascha, Weiss, Thomas S., Bischoff, Stephan C., Lauer, Ulrich M., Bitzer, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3758278/
https://www.ncbi.nlm.nih.gov/pubmed/24023672
http://dx.doi.org/10.1371/journal.pone.0073097
_version_ 1782282330877984768
author Venturelli, Sascha
Berger, Alexander
Böcker, Alexander
Busch, Christian
Weiland, Timo
Noor, Seema
Leischner, Christian
Schleicher, Sabine
Mayer, Mascha
Weiss, Thomas S.
Bischoff, Stephan C.
Lauer, Ulrich M.
Bitzer, Michael
author_facet Venturelli, Sascha
Berger, Alexander
Böcker, Alexander
Busch, Christian
Weiland, Timo
Noor, Seema
Leischner, Christian
Schleicher, Sabine
Mayer, Mascha
Weiss, Thomas S.
Bischoff, Stephan C.
Lauer, Ulrich M.
Bitzer, Michael
author_sort Venturelli, Sascha
collection PubMed
description The polyphenolic alcohol resveratrol has demonstrated promising activities for the prevention and treatment of cancer. Different modes of action have been described for resveratrol including the activation of sirtuins, which represent the class III histone deacetylases (HDACs). However, little is known about the activity of resveratrol on the classical HDACs of class I, II and IV, although these classes are involved in cancer development or progression and inhibitors of HDACs (HDACi) are currently under investigation as promising novel anticancer drugs. We could show by in silico docking studies that resveratrol has the chemical structure to inhibit the activity of different human HDAC enzymes. In vitro analyses of overall HDAC inhibition and a detailed HDAC profiling showed that resveratrol inhibited all eleven human HDACs of class I, II and IV in a dose-dependent manner. Transferring this molecular mechanism into cancer therapy strategies, resveratrol treatment was analyzed on solid tumor cell lines. Despite the fact that hepatocellular carcinoma (HCC) is known to be particularly resistant against conventional chemotherapeutics, treatment of HCC with established HDACi already has shown promising results. Testing of resveratrol on hepatoma cell lines HepG2, Hep3B and HuH7 revealed a dose-dependent antiproliferative effect on all cell lines. Interestingly, only for HepG2 cells a specific inhibition of HDACs and in turn a histone hyperacetylation caused by resveratrol was detected. Additional testing of human blood samples demonstrated a HDACi activity by resveratrol ex vivo. Concluding toxicity studies showed that primary human hepatocytes tolerated resveratrol, whereas in vivo chicken embryotoxicity assays demonstrated severe toxicity at high concentrations. Taken together, this novel pan-HDACi activity opens up a new perspective of resveratrol for cancer therapy alone or in combination with other chemotherapeutics. Moreover, resveratrol may serve as a lead structure for chemical optimization of bioavailability, pharmacology or HDAC inhibition.
format Online
Article
Text
id pubmed-3758278
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-37582782013-09-10 Resveratrol as a Pan-HDAC Inhibitor Alters the Acetylation Status of Jistone Proteins in Human-Derived Hepatoblastoma Cells Venturelli, Sascha Berger, Alexander Böcker, Alexander Busch, Christian Weiland, Timo Noor, Seema Leischner, Christian Schleicher, Sabine Mayer, Mascha Weiss, Thomas S. Bischoff, Stephan C. Lauer, Ulrich M. Bitzer, Michael PLoS One Research Article The polyphenolic alcohol resveratrol has demonstrated promising activities for the prevention and treatment of cancer. Different modes of action have been described for resveratrol including the activation of sirtuins, which represent the class III histone deacetylases (HDACs). However, little is known about the activity of resveratrol on the classical HDACs of class I, II and IV, although these classes are involved in cancer development or progression and inhibitors of HDACs (HDACi) are currently under investigation as promising novel anticancer drugs. We could show by in silico docking studies that resveratrol has the chemical structure to inhibit the activity of different human HDAC enzymes. In vitro analyses of overall HDAC inhibition and a detailed HDAC profiling showed that resveratrol inhibited all eleven human HDACs of class I, II and IV in a dose-dependent manner. Transferring this molecular mechanism into cancer therapy strategies, resveratrol treatment was analyzed on solid tumor cell lines. Despite the fact that hepatocellular carcinoma (HCC) is known to be particularly resistant against conventional chemotherapeutics, treatment of HCC with established HDACi already has shown promising results. Testing of resveratrol on hepatoma cell lines HepG2, Hep3B and HuH7 revealed a dose-dependent antiproliferative effect on all cell lines. Interestingly, only for HepG2 cells a specific inhibition of HDACs and in turn a histone hyperacetylation caused by resveratrol was detected. Additional testing of human blood samples demonstrated a HDACi activity by resveratrol ex vivo. Concluding toxicity studies showed that primary human hepatocytes tolerated resveratrol, whereas in vivo chicken embryotoxicity assays demonstrated severe toxicity at high concentrations. Taken together, this novel pan-HDACi activity opens up a new perspective of resveratrol for cancer therapy alone or in combination with other chemotherapeutics. Moreover, resveratrol may serve as a lead structure for chemical optimization of bioavailability, pharmacology or HDAC inhibition. Public Library of Science 2013-08-30 /pmc/articles/PMC3758278/ /pubmed/24023672 http://dx.doi.org/10.1371/journal.pone.0073097 Text en © 2013 Venturelli et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Venturelli, Sascha
Berger, Alexander
Böcker, Alexander
Busch, Christian
Weiland, Timo
Noor, Seema
Leischner, Christian
Schleicher, Sabine
Mayer, Mascha
Weiss, Thomas S.
Bischoff, Stephan C.
Lauer, Ulrich M.
Bitzer, Michael
Resveratrol as a Pan-HDAC Inhibitor Alters the Acetylation Status of Jistone Proteins in Human-Derived Hepatoblastoma Cells
title Resveratrol as a Pan-HDAC Inhibitor Alters the Acetylation Status of Jistone Proteins in Human-Derived Hepatoblastoma Cells
title_full Resveratrol as a Pan-HDAC Inhibitor Alters the Acetylation Status of Jistone Proteins in Human-Derived Hepatoblastoma Cells
title_fullStr Resveratrol as a Pan-HDAC Inhibitor Alters the Acetylation Status of Jistone Proteins in Human-Derived Hepatoblastoma Cells
title_full_unstemmed Resveratrol as a Pan-HDAC Inhibitor Alters the Acetylation Status of Jistone Proteins in Human-Derived Hepatoblastoma Cells
title_short Resveratrol as a Pan-HDAC Inhibitor Alters the Acetylation Status of Jistone Proteins in Human-Derived Hepatoblastoma Cells
title_sort resveratrol as a pan-hdac inhibitor alters the acetylation status of jistone proteins in human-derived hepatoblastoma cells
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3758278/
https://www.ncbi.nlm.nih.gov/pubmed/24023672
http://dx.doi.org/10.1371/journal.pone.0073097
work_keys_str_mv AT venturellisascha resveratrolasapanhdacinhibitoralterstheacetylationstatusofjistoneproteinsinhumanderivedhepatoblastomacells
AT bergeralexander resveratrolasapanhdacinhibitoralterstheacetylationstatusofjistoneproteinsinhumanderivedhepatoblastomacells
AT bockeralexander resveratrolasapanhdacinhibitoralterstheacetylationstatusofjistoneproteinsinhumanderivedhepatoblastomacells
AT buschchristian resveratrolasapanhdacinhibitoralterstheacetylationstatusofjistoneproteinsinhumanderivedhepatoblastomacells
AT weilandtimo resveratrolasapanhdacinhibitoralterstheacetylationstatusofjistoneproteinsinhumanderivedhepatoblastomacells
AT noorseema resveratrolasapanhdacinhibitoralterstheacetylationstatusofjistoneproteinsinhumanderivedhepatoblastomacells
AT leischnerchristian resveratrolasapanhdacinhibitoralterstheacetylationstatusofjistoneproteinsinhumanderivedhepatoblastomacells
AT schleichersabine resveratrolasapanhdacinhibitoralterstheacetylationstatusofjistoneproteinsinhumanderivedhepatoblastomacells
AT mayermascha resveratrolasapanhdacinhibitoralterstheacetylationstatusofjistoneproteinsinhumanderivedhepatoblastomacells
AT weissthomass resveratrolasapanhdacinhibitoralterstheacetylationstatusofjistoneproteinsinhumanderivedhepatoblastomacells
AT bischoffstephanc resveratrolasapanhdacinhibitoralterstheacetylationstatusofjistoneproteinsinhumanderivedhepatoblastomacells
AT lauerulrichm resveratrolasapanhdacinhibitoralterstheacetylationstatusofjistoneproteinsinhumanderivedhepatoblastomacells
AT bitzermichael resveratrolasapanhdacinhibitoralterstheacetylationstatusofjistoneproteinsinhumanderivedhepatoblastomacells